The landscape of contract development and manufacturing organizations (CDMOs) is undergoing a significant transformation due to the rise of multispecific antibody therapeutics. As these innovative biologics gain momentum, manufacturers are compelled to rethink their development frameworks, integrating advanced molecular engineering, sophisticated analytical techniques, and optimized upstream and downstream processing strategies.
Understanding Multispecifics
Multispecific antibodies are designed to interact with multiple targets simultaneously, offering a new frontier in therapeutic development. The first generation of these multitarget biologics, bispecific antibodies, has already made a substantial impact, particularly with the surge of programs launched by Chinese biotechnology firms from 2020 to 2025. Leading CDMOs, such as WuXi Biologics, Lonza Biologics, and Samsung Biologics, have proactively developed technology platforms tailored for the production of bispecific and multispecific antibodies.
The Next Generation of Multispecifics
The evolving landscape now includes trispecific antibodies, T-cell engagers that provide co-stimulation, natural killer (NK) cell engagers, and dual agonists. While these advancements present exciting opportunities, they also introduce complexities beyond those seen with bispecific antibodies, such as mispairing, instability, and product heterogeneity. This necessitates a reevaluation of existing development strategies within CDMOs.
Laura Daley, Senior Director of Cell Biology & Product Development at Catalent, emphasizes that the most significant challenges associated with multispecifics lie in cell line development (CLD), analytical characterization, and downstream purification. These areas are critical for establishing a robust manufacturing control strategy.
Overcoming Development Challenges
Multispecific antibodies often face issues related to chain mispairing and product heterogeneity. To tackle these challenges, engineering techniques like knobs-into-holes are frequently employed. This method modifies the structure of protein components to ensure proper pairing during manufacturing. Additionally, utilizing common light chains can help prevent mispairing by standardizing components.
According to Randal Bass, Executive Vice President of Process Design and Innovation at Just-Evotec Biologics, achieving controlled expression of multiple chains at specified ratios is essential yet challenging. Catalent’s GPEx® Lightning platform addresses these needs through precise gene integration and stable cell line generation.
The Role of Bioprocessing Platforms
Advancements in bioprocessing platforms are crucial for accommodating the needs of multispecifics. The integration of high-throughput transfection methods and automation enhances the efficiency of screening various DNA vector chain ratios, ensuring the correct assembly of these complex molecules.
While traditional monoclonal antibodies typically exhibit high expression levels, multispecifics can still achieve commendable expression rates with modern cell lines and vector systems. Innovations such as intensified bioreactor processes, including ATF (Alternating Tangential Flow) and TFF (Tangential Flow Filtration) perfusion, further enhance volumetric productivity.
Importance of Analytical Techniques
The characterization of multispecifics demands advanced analytical methodologies. Mass spectrometry has emerged as a foundational tool, offering insights into molecular pairing and composition. Techniques such as whole mass analysis and capillary electrophoresis are instrumental in quantifying impurities and assessing the integrity of the final product. Furthermore, multi-attribute methods are essential for identifying undesirable modifications prevalent in complex molecules.
Daley points out that the analytical requirements for multispecifics are significantly more intricate than those for traditional monoclonal antibodies. Key focus areas include confirming chain pairing, structural characterization, variant identification, aggregate analysis, and evaluating product heterogeneity. Catalent has enhanced its analytical development capabilities to facilitate rapid feedback loops throughout the development and manufacturing processes.
Navigating Quality Control Challenges
The rise of multispecifics has also altered the quality control (QC) landscape for CDMOs, particularly concerning binding and potency assays. Variations in physical characteristics can influence binding efficacy and potency, necessitating the development of additional assays for each new target.
Daley notes that there is an increasing demand for expedited decision-making, enhanced process understanding, and reduced release timelines. While the industry is gradually adopting these enhancements, technologies such as process analytical technologies, automated data analysis, real-time monitoring, and AI-driven analytics are becoming increasingly pivotal.
Upstream and Downstream Process Development
Intensified upstream technologies are gaining traction for their potential to boost productivity and shorten timelines; however, they are not always essential for commercial success. Catalent’s GPEx® Lightning technology consistently generates high-expressing cell lines for complex multispecific modalities, integrating development and manufacturing processes effectively.
Challenges persist, including low titers, stability issues, and proteolytic clipping. Intensifying upstream processes, such as perfusion, can mitigate low titers, while continuous capture steps can address stability concerns.
Daley emphasizes that downstream processing often presents greater challenges than upstream processing. Purification strategies for multispecifics must be tailored to manage issues related to chain mispairing, aggregate control, and product-related variants. Successful CDMOs invest in flexible downstream infrastructures and high-throughput development capabilities to optimize chromatography workflows quickly.
Conclusion
The emergence of multispecific antibodies is reshaping the CDMO development landscape, demanding innovative approaches to bioprocessing and analytical methodologies. As manufacturers adapt to these changes, they must prioritize flexibility, efficiency, and precision in their strategies. The future of biologics lies in the ability to navigate the complexities of multispecifics while maintaining high standards of quality and performance.
- Multispecific antibodies are redefining CDMO processes.
- Advanced engineering and analytics are critical for success.
- Flexibility in upstream and downstream workflows is essential.
- Automation and AI are enhancing decision-making speed.
- A focus on quality control is vital for multispecific development.
Read more → www.biospace.com